Cart
sales@molnova.com
Sunvozertinib
CAS No. 2370013-12-8
Sunvozertinib( —— )
Catalog No. M35766 CAS No. 2370013-12-8
Sunvozertinib (DZD9008) is a potent ErbBs and BTK inhibitor, with inhibitory effects on EGFR, Her2, and mutant epidermal growth factor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 46 | Get Quote |
|
| 5MG | 55 | Get Quote |
|
| 10MG | 78 | Get Quote |
|
| 25MG | 122 | Get Quote |
|
| 50MG | 205 | Get Quote |
|
| 100MG | 353 | Get Quote |
|
| 500MG | 1314 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameSunvozertinib
-
NoteResearch use only, not for human use.
-
Brief DescriptionSunvozertinib (DZD9008) is a potent ErbBs and BTK inhibitor, with inhibitory effects on EGFR, Her2, and mutant epidermal growth factor.
-
DescriptionSunvozertinib (DZD9008) is a potent ErbBs (EGFR, Her2, especially mutant forms) and BTK inhibitor. Sunvozertinib shows IC50s of 20.4, 20.4, 1.1, 7.5, and 80.4 nM for EGFR exon 20 NPH insertion, EGFR exon 20 ASV insertion, EGFR L858R and T790M mutations, and Her2 Exon20 YVMA, and EGFR WT A431, respectively (patent WO2019149164A1, example 52).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR | BTK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2370013-12-8
-
Formula Weight584.08
-
Molecular FormulaC29H35ClFN7O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (85.60 mM; Ultrasonic (<80°C)
-
SMILESCOc1cc(N2CC[C@H](C2)N(C)C)c(NC(=O)C=C)cc1Nc1nccc(Nc2cc(Cl)c(F)cc2C(C)(C)O)n1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Zhengtao LI, et al. Erbb/btk inhibitors. WO2019149164A1.
molnova catalog
related products
-
(Rac)-JBJ-04-125-02
JBJ-04-125-02 is effective as a single agent in both in vitro and in vivo models of EGFR-mutant lung cancer.
-
Petosemtamab
Petosemtamab (MCLA 158) is a highly potent monoclonal antibody against EGFR (Kd: 0.22 nM) and LGR5 (Kd: 0.86 nM). Petosemtamab promotes EGFR signaling disruption and receptor breakdown in LGR5+ cancer cells.
-
AST-1306
AST-1306 is a novel irreversible inhibitor of EGFR and ErbB2 with IC50 of 0.5 nM and 3 nM, also effective in mutation EGFR T790M/L858R.
